PPBTPURPLE BIOTECH LTD.

Nasdaq purple-biotech.com


$ 0.78 $ 0.04 (5.37 %)    

Tuesday, 28-May-2024 15:59:40 EDT
QQQ $ 454.82 $ 1.73 (0.38 %)
DIA $ 398.57 $ -2.04 (-0.52 %)
SPY $ 530.36 $ 0.37 (0.07 %)
TLT $ 91.26 $ -1.31 (-1.43 %)
GLD $ 225.37 $ 2.27 (1.05 %)
$ 0.785
$ 0.82
$ 0.00 x 0
$ 0.00 x 0
$ 0.76 - $ 0.82
$ 0.30 - $ 1.88
182,521
na
19.81M
$ 1.12
$ 1.84
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-q1-2024-gaap-epads-014-beats-015-estimate-cash-9985m

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 chardan-capital-maintains-buy-on-purple-biotech-maintains-11-price-target

Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-q4-eps-019-inline

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-says-determined-100mgkg-is-the-recommended-phase-2-dose-for-nt219-in-combination-with-cetuximab-in-the-treatment-of-head-and-neck-cancer-based-on-its-phase-12-dose-escalation-study

NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being conclud...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 hc-wainwright--co-maintains-buy-on-purple-biotech-raises-price-target-to-10

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and raises the price target f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION